Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 12 years of age and older~* Clinical and/or electrographic seizures~Exclusion Criteria:~* Life expectancy of less than 24 hours~* Anoxic brain injury as primary cause of SE~* Recent (\<24 hour) traumatic brain injury as the primary cause of SE~* Administered anesthesia for the treatment of SE

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Ganaxolone active (Type: EXPERIMENTAL): Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
- IV Placebo, non-active (Type: PLACEBO_COMPARATOR): Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.

Based on this trial design, predict the completion outcome and termination type (if applicable).